Risk of myocarditis and pericarditis in mRNA COVID-19-vaccinated and unvaccinated populations: a systematic review and meta-analysis
Open accessThe DOI matches its Crossref record; 86 of the 90 references it cites were found in a registry or an index.
Abstract
Objective: To summarise the available evidence on the risk of myocarditis and/or pericarditis following mRNA COVID-19 vaccination, compared with the risk among unvaccinated individuals in the absence of COVID-19 infection. Design: Systematic review and meta-analysis. Data sources: Electronic databases (Medline, Embase, Web of Science and WHO Global Literature on Coronavirus Disease), preprint repositories (medRxiv and bioRxiv), reference lists and grey literature were searched from 1 December 2020 until 31 October 2022. Study selection: Epidemiological studies of individuals of any age who received at least one dose of an mRNA COVID-19 vaccine, reported a risk of myo/pericarditis and compared the risk of myo/pericarditis to individuals who did not receive any dose of an mRNA COVID-19 vaccine. Data extraction and synthesis: Two reviewers independently conducted screening and data extraction. The rate of myo/pericarditis among vaccinated and unvaccinated groups was recorded, and the rate ratios were calculated. Additionally, the total number of individuals, case ascertainment criteria, percentage of males and history of SARS-CoV-2 infection were extracted for each study. Meta-analysis was done using a random-effects model. Results: Seven studies met the inclusion criteria, of which six were included in the quantitative synthesis. Our meta-analysis indicates that within 30-day follow-up period, vaccinated individuals were twice as likely to develop myo/pericarditis in the absence of SARS-CoV-2 infection compared to unvaccinated individuals, with a rate ratio of 2.05 (95% CI 1.49–2.82). Conclusion: Although the absolute number of observed myo/pericarditis cases remains quite low, a higher risk was detected in those who received mRNA COVID-19 vaccinations compared with unvaccinated individuals in the absence of SARS-CoV-2 infection. Given the effectiveness of mRNA COVID-19 vaccines in preventing severe illnesses, hospitalisations and deaths, future research should focus on accurately determining the rates of myo/pericarditis linked to mRNA COVID-19 vaccines, understanding the biological mechanisms behind these rare cardiac events and identifying those most at risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A systematic review by Alami et al. [38] concluded that mRNA vaccinated individuals were twice as likely to develop myocarditis/ pericarditis compared with unvaccinated individuals, with a rate ratio of 2.05 (95 % CI 1.49 -2.82).”
From COVID-19 vaccines and adverse events of special interest: A multinational Global Vaccine Data Network (GVDN) cohort study of 99 million vaccinated individuals (2024) · cites this paper as [38]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“As mRNA COVID-19 vaccines have been associated with cases of myocarditis in young adults, 19 we monitored for chest pain and shortness of breath in the 7 days after vaccination as indicators of myocarditis and pericarditis.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Bramer, W. M., Rethlefsen, M. L., Kleijnen, J., & Franco, O. H. (2017) · Systematic Reviews · doi:10.1186/s13643-017-0644-y · Cited by 2,114
De-duplication of database search results for systematic reviews in EndNote
Bramer, W. M., Giustini, D., de Jonge, G. B., Holland, L., & Bekhuis, T. (2016) · Journal of the Medical Library Association : JMLA · doi:10.3163/1536-5050.104.3.014 · Cited by 2,103
Rothman, K. J., Greenland, S., & Lash, T. L. (1998) · Cited by 2,096
Long-term cardiovascular outcomes of COVID-19
Xie, Y., Xu, E., Bowe, B., & Al-Aly, Z. (2022) · Nature Medicine · doi:10.1038/s41591-022-01689-3 · Cited by 2,029
Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
Barda, N., Dagan, N., Ben-Shlomo, Y., Kepten, E., Waxman, J., Ohana, R., Hernán, M. A., Lipsitch, M., Kohane, I., Netzer, D., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2110475 · Cited by 1,027 · cited 2×
“…analysis to shorter risk intervals by including only confirmed cases of myo/pericarditis that were reported within 30 days following an mRNA vaccination, and excluding the two studies that used historical comparator cohort group, the overall RR was still significant (RR=2.05, 95% CI 1.49 to 2.82).”
BackgroundResultInfluentialDuration of Protection against Mild and Severe Disease by Covid-19 Vaccines
Andrews, N., Tessier, E., Stowe, J., Gower, C., Kirsebom, F., Simmons, R., Gallagher, E., Thelwall, S., Groves, N., Dabrera, G., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2115481 · Cited by 807
Research works printed but not linked: 3
- StataCorp LLC . STATA meta-analysis reference manual release 17. Statistical Software. Texas, United States: Published by Stata Press, 2021.
- Office of Health Assessment and Translation (OHAT) . Handbook for Conducting a Literature-Based Health Assessment Using OHAT Approach for Systematic Review and Evidence Integration. 2019.
- Husby A , Hansen JV , Fosbøl E , et al . SARS-Cov-2 vaccination and myocarditis or Myopericarditis: population based cohort study. Bmj. BMJ 2021:e068665. doi:10.1136/bmj-2021-068665 · DOI · Paper page
Cited by
Faksova, K., Walsh, D., Jiang, Y., Griffin, J., Phillips, A., Gentile, A., Kwong, J. C., Macartney, K., Naus, M., Grange, Z., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.01.100 · Cited by 212
Oda, Y., Kumagai, Y., Kanai, M., Iwama, Y., Okura, I., Minamida, T., Yagi, Y., Kurosawa, T., Greener, B., Zhang, Y., et al. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00650-3 · Cited by 146
Jung, S., Jeon, J. J., Kim, Y. H., Choe, S. J., & Lee, S. (2024) · Nature Communications · doi:10.1038/s41467-024-50656-8 · Cited by 59
Hodel, K. V. S., Fiuza, B. S. D., Conceição, R. S., Aleluia, A. C. M., Pitanga, T. N., Fonseca, L. M. D. S., Valente, C. O., Rezende, C. S. M. E., & Machado, B. A. S. (2024) · Pharmaceuticals · doi:10.3390/ph17060807 · Cited by 56
Nanocarrier imaging at single-cell resolution across entire mouse bodies with deep learning
Luo, J., Molbay, M., Chen, Y., Horvath, I., Kadletz, K., Kick, B., Zhao, S., Al-Maskari, R., Singh, I., Ali, M., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-024-02528-1 · Cited by 53
“The observed LNP accumulation and proteome changes in heart tissue suggest a potential mechanism by which LNP-based mRNA vaccines could contribute to the reported cardiac complications 42–46 .”
Metadata
- Authors
- Alami, A., Krewski, D., Farhat, N., Mattison, D., Wilson, K., Gravel, C. A., Farrell, P. J., Crispo, J. A. G., Haddad, N., Perez-Lloret, S., & Villeneuve, P. J.
- Affiliations
- Carleton University (CA)
- University of Ottawa (CA)
- University of British Columbia (CA)
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
- Corresponding author
- Alami, Abdallah
- ORCID
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2023-06
- Volume
- 13
- Issue
- 6
- Pages
- e065687
- ISSN
- 2044-6055 (ISSN-L)
- PMC
- PMC10314577
- OpenAlex
- W4381434687
- Cited by
- 44
- References
- 90
- Citations by year
- 2026: 6 · 2025: 11 · 2024: 22 · 2023: 5
- FWCI
- 2.30
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- BMJ Open (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc-sa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- myocarditis, pericarditis, COVID-19 mRNA vaccine, vaccine safety, unvaccinated individuals, COVID-19 pandemic, adverse cardiac events, rate ratios
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, Humans, Male, Myocarditis, Pericarditis, RNA, Messenger, Vaccination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Risk of myocarditis and pericarditis in mRNA COVID-19-vaccinated and unvaccinated populations: a systematic review and meta-analysis. https://app.cochat.ai/papers/10.1136/bmjopen-2022-065687
- The paper
- Alami, A., Krewski, D., Farhat, N., Mattison, D., Wilson, K., Gravel, C. A., Farrell, P. J., Crispo, J. A. G., Haddad, N., Perez-Lloret, S., & Villeneuve, P. J. (2023). Risk of myocarditis and pericarditis in mRNA COVID-19-vaccinated and unvaccinated populations: a systematic review and meta-analysis. BMJ Open. https://doi.org/10.1136/bmjopen-2022-065687
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.